{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T16:40:01Z","timestamp":1750092001921,"version":"3.41.0"},"reference-count":14,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Introduction: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) poses considerable treatment challenges, with disheartening odds of long-term survival. Numerous strategies exist, including non-cross-resistant combination chemoimmunotherapy regimens, autologous stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy, but some patients are not appropriate candidates or cannot sustain response to treatment. Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, has been given accelerated approval by the US Food and Drug Administration for relapsed or refractory DLBCL. Case Presentation: We present the case of a 61-year-old male diagnosed with stage 4 \u201cdouble-hit\u201d DLBCL with MYC and BCL6 rearrangement, who initially received one cycle of rituximab HyperCVAD (initiated July 23, 2021). He then received dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) followed by high-dose methotrexate and initially responded but relapsed several months later. As the patient was not a candidate for transplant, subsequent treatment rounds included rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) and CD19 CAR T-cell therapy; tafasitamab-cxix and lenalidomide; and polatuzumab vedotin plus bendamustine and rituximab (pola-BR). Despite intermittent treatment response, his disease continued to progress. He began treatment with epcoritamab through the early access program but showed early signs of continued progression; his status deteriorated until further treatment had to be withheld. Within approximately 1 month, he could resume treatment, achieving a Deauville score of 1 approximately 3 months after beginning epcoritamab, and continues follow-up nearly 2 years later. Conclusion: T-cell engager therapies, such as epcoritamab, can play a role in managing patients with refractory DLBCL, including those refractory to CAR T-cell therapy. <\/jats:p>","DOI":"10.1159\/000545372","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T17:06:39Z","timestamp":1743267999000},"page":"744-750","source":"Crossref","is-referenced-by-count":0,"title":["Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report"],"prefix":"10.1159","volume":"18","author":[{"given":"Jeremy","family":"Rosiecki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Kammers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Chee","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia","family":"Wyckoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3648"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.24054"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00430-6"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004665"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1658"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/20363613231193566"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15996"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.200"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000971368.08106.5c"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.909008"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545372","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T16:02:31Z","timestamp":1750089751000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000545372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000545372","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.28685303","asserted-by":"subject"}]},"ISSN":["1662-6575"],"issn-type":[{"type":"electronic","value":"1662-6575"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}